Related Experiment Video
Updated: Apr 23, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier
Jianqin Lu1, Wenchen Zhao, Yixian Huang
1Center for Pharmacogenetics, ‡Department of Pharmaceutical Sciences, School of Pharmacy, and §University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh, Pennsylvania 15261, United States.
Abstract:
Doxorubicin (DOX) is one of the most commonly used antineoplastic agents, but its clinical application is oftentimes coupled with severe side effects. Selective delivery of DOX to tumors via nanosized drug carrier represents an attractive approach to this problem. Previously, we developed a dual functional nanomicellar carrier, PEG5K-embelin2 (PEG5K-EB2), which was able to deliver paclitaxel (PTX) selectively to tumors and to achieve an enhanced therapeutic effect. In the present study, we examined the utility of PEG5K-EB2 to deliver DOX to tumors. In addition, folic acid (FA) was coupled to the surface of the PEG5K-EB2 micelles (FA-PEG5K-EB2) to further improve the selective targetability of the system. DOX-loaded PEG5K-EB2 micelles were uniformly spherical particles with a diameter of approximately 20 nm. Incorporation of FA had minimal effect on the size of the particles. The DOX loading efficiency was as high as 91.7% and 93.5% for PEG5K-EB2 and FA-PEG5K-EB2, respectively. DOX formulated in PEG5K-EB2 micelles (with or without FA decoration) demonstrated sustained kinetics of DOX release compared to free DOX. FA-PEG5K-EB2 significantly facilitated the intracellular uptake of DOX over free DOX and PEGylated liposomal DOX (Doxil) in breast cancer cells, 4T1.2, and drug resistant cells, NCI/ADR-RES. P-gp ATPase assay showed that PEG5K-EB2 significantly inhibited the function of the P-gp efflux pump. The maximum tolerated dose of DOX-loaded PEG5K-EB2 micelles was 15 mg/kg in mice, which was 1.5-fold greater than that for free DOX. Pharmacokinetics (PK) and biodistribution studies showed that both types of DOX-loaded micelles, especially FA-PEG5K-EB2, were able to significantly prolong the blood circulation time of DOX and facilitate its preferential accumulation at the tumor tissue. Finally, DOX/PEG5K-EB2 mixed micelles demonstrated significantly enhanced tumor growth inhibitory effect with minimal toxicity in comparison to free DOX and Doxil and the antitumor activity was further enhanced after the decoration by folic acid. Our data suggest that FA-PEG5K-EB2 micelles represent a promising DOX delivery system that warrants more study in the future.
Insights
This study developed folic acid-decorated PEG5K-embelin2 (FA-PEG5K-EB2) nanomicelles for enhanced doxorubicin (DOX) delivery. FA-PEG5K-EB2 micelles improved DOX tumor targeting, reduced toxicity, and boosted anti-cancer efficacy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Doxorubicin (DOX) is a vital chemotherapeutic agent, but its use is limited by severe side effects.
- Nanosized drug carriers offer a strategy for selective DOX delivery to tumors, potentially mitigating toxicity.
- Previous work established PEG5K-embelin2 (PEG5K-EB2) as a dual-functional nanomicellar carrier for paclitaxel delivery.
Purpose of the Study:
- To evaluate the efficacy of PEG5K-EB2 nanomicelles for doxorubicin (DOX) delivery.
- To enhance DOX tumor targeting and therapeutic effects by conjugating folic acid (FA) to create FA-PEG5K-EB2 micelles.
- To assess the safety, pharmacokinetics, and anti-tumor activity of these novel DOX-loaded nanocarriers.
Main Methods:
- Synthesis and characterization of DOX-loaded PEG5K-EB2 and FA-PEG5K-EB2 nanomicelles.
- In vitro evaluation of DOX loading efficiency, release kinetics, and cellular uptake in cancer and drug-resistant cell lines.
- In vivo studies including maximum tolerated dose, pharmacokinetic profiling, biodistribution, and anti-tumor efficacy assessment in a mouse model.
Main Results:
- DOX-loaded FA-PEG5K-EB2 micelles exhibited high loading efficiency and sustained DOX release.
- FA-PEG5K-EB2 significantly enhanced intracellular DOX uptake in cancer cells compared to free DOX and Doxil.
- In vivo studies demonstrated prolonged circulation, preferential tumor accumulation, increased maximum tolerated dose, and superior tumor growth inhibition with minimal toxicity for FA-PEG5K-EB2 micelles.
Conclusions:
- FA-PEG5K-EB2 nanomicelles represent a promising drug delivery system for doxorubicin.
- The folic acid decoration effectively improves DOX's tumor-targeting capability and therapeutic index.
- This novel nanocarrier system warrants further investigation for clinical translation in cancer therapy.
More Related Videos
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Targeted Cancer Therapies
There are several types of targeted therapies against...